Where can researchers source third-party tested BPC-157?

Midwest Peptide supplies research-grade BPC-157 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Memorial Day: 15% off code MEMDAY15Memorial Day Sale — 15% off site-wide with code MEMDAY15

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

BPC-157 Tissue Repair Research: Animal Model Review | Midwest Peptide

TB-500 Research: Reviewing the Thymosin Beta-4 Fragment LiteraturePrev|GHK-Cu Research Studies: Reviewing the Literature on Copper Peptides and Dermal Fibroblast ActivityNext

BPC-157 Research: A Review of Tissue Repair Studies in Animal Models

Q: Is BPC-157 approved for human use?

No. BPC-157 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

KLOW Blend · Published April 8, 2026 · Updated May 18, 2026 · 9 min read

Quick Answer

BPC-157 tissue repair research examines this pentadecapeptide across rodent tendon, ligament, muscle, and gastrointestinal repair models. Studies measure angiogenic biomarkers, fibroblast activity, growth factor expression, and the localized mechanism of action that drives BPC-157 research applications across multiple injury endpoints. For research use only, not for human consumption.

BPC-157 Research: A Review of Tissue Repair Studies in Animal Models

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

What Is BPC-157?
Tendon Repair Studies in Rodent Models
Ligament and Muscle Repair Endpoints
Gastrointestinal Research Models
Angiogenesis Markers in BPC-157 Research
BPC-157 in the KLOW Blend
Open Research Questions
Conclusion
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

BPC-157 research has produced one of the most active and discussed bodies of preclinical literature on tissue repair peptides over the past two decades. As the gastric protective and tissue repair component of the KLOW peptide blend, BPC-157 brings a substantial body of rodent and in vitro evidence to the formulation. This article reviews the published literature on BPC-157, with a focus on tendon, ligament, and muscle repair endpoints, gastrointestinal tissue research, angiogenesis markers, and the proposed mechanism of localized action that defines its profile in research models.

Frequently Asked Questions

What is BPC-157 in research contexts?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a protective sequence found in human gastric juice. It is studied in preclinical rodent models for its effects on tissue repair, vascular signaling, and cytoprotection.

Why is BPC-157 a foundational component of the KLOW blend?

BPC-157 contributes the localized cytoprotective and angiogenic signaling needed for tissue repair across multiple injury models. Its inclusion in KLOW provides the tendon, ligament, muscle, and gastrointestinal repair foundation that complements the other three peptides.

How does BPC-157 in KLOW differ from BPC-157 alone in research?

Within KLOW, BPC-157 acts alongside KPV's anti-inflammatory effects, GHK-Cu's collagen synthesis, and TB-500's actin-mediated cell migration, producing a multi-mechanism approach to tissue repair across the inflammation, proliferation, and remodeling phases simultaneously.

Is BPC-157 approved for human use?

Glossary

Key terms used in this article.

Pentadecapeptide: A peptide chain composed of 15 amino acid residues linked by peptide bonds.
Cytoprotection: The biological process by which cells are protected from injury caused by chemical, ischemic, or oxidative insults.
Angiogenesis: The formation of new blood vessels from pre-existing vasculature, central to tissue repair.
VEGF: Vascular Endothelial Growth Factor, a signaling glycoprotein that stimulates new blood vessel formation.
Nitric Oxide (NO): A short-lived gaseous signaling molecule that triggers vasodilation and supports endothelial function.
Multi-Peptide Blend: A research formulation combining two or more peptides to study additive or synergistic biological effects.
KPV: A tripeptide (lysine-proline-valine) corresponding to the C-terminal of alpha-MSH, studied for anti-inflammatory effects.
Tissue Repair: The biological process restoring damaged tissue through inflammation, proliferation, and remodeling.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. BPC-157 is intended exclusively for in vitro and preclinical research. It is not approved for human use, is not a drug, and should never be administered to humans or to animals outside of a formal research protocol.

What Is BPC-157?

BPC-157 is a stable pentadecapeptide composed of 15 amino acids. The acronym stands for Body Protection Compound 157, and the peptide was identified in the 1990s by a research group studying protective sequences in human gastric juice. The full protective protein from which BPC-157 was derived has not been completely characterized in the published literature, but the 15 amino acid fragment has been the subject of dozens of preclinical studies, particularly in rodent models of gastrointestinal and connective tissue injury.

The original research interest in BPC-157 emerged from observations that gastric juice contains protective factors that are not fully accounted for by the better known mucus and bicarbonate barriers. Investigators identified peptide fragments derived from a protective protein that retained activity when isolated, and BPC-157 was selected for further study based on its stability and its activity in early rodent injury models. Subsequent decades of research have characterized its effects across multiple tissue types, with rodent injury studies forming the backbone of the published literature.

A defining feature of BPC-157 in preclinical research is its stability. The peptide is generally described in the literature as being relatively resistant to degradation in gastric and other body fluid conditions, which has made it useful as a research tool for studies that require sustained activity rather than rapid clearance. This stability has also influenced the methods researchers use to administer BPC-157 in animal model studies.

Tendon Repair Studies in Rodent Models

Tendon repair has been one of the most studied endpoints in BPC-157 research, in part because tendon injuries are notoriously slow to heal and represent an unmet need in regenerative medicine research. Rodent models of Achilles tendon transection and rotator cuff injury have been used to evaluate BPC-157 effects on tendon healing markers, including biomechanical strength recovery, collagen organization, fibroblast proliferation, and growth factor expression at the injury site.

Published rodent studies have generally reported that BPC-157 administration is associated with improved tendon repair endpoints relative to untreated controls in research models. These improvements have been observed in measurements of tensile strength recovery, collagen fiber alignment in histological sections, and expression of growth factors involved in tendon healing. The mechanism proposed in the literature involves modulation of vascular endothelial growth factor signaling, fibroblast migration to the injury site, and angiogenesis at the repair zone.

The tendon repair literature on BPC-157 has used a range of standardized rodent injury protocols, which has supported some degree of comparability across studies. Investigators in this field have continued to refine the experimental designs over time, with newer studies using more rigorous biomechanical endpoints and larger cohort sizes than some of the earlier publications. The general pattern of findings in the literature is consistent with BPC-157 acting as a localized modulator of repair processes at the injury site in research models.

Ligament and Muscle Repair Endpoints

Beyond tendon studies, BPC-157 research has covered ligament repair and skeletal muscle injury models in rodents. The endpoints in these studies typically include histological measures of repair tissue organization, biomechanical recovery of strength, and molecular markers of inflammation and growth factor expression at the injury site.

Published rodent studies on ligament repair have reported that BPC-157 administration is associated with improved structural and functional recovery in research models, particularly in medial collateral ligament transection studies. The proposed mechanism is similar to that described in tendon studies, involving angiogenesis, fibroblast activity, and growth factor modulation at the site of injury.

Skeletal muscle injury models have also been used to evaluate BPC-157 in research settings. In these studies, BPC-157 has been associated with reduced muscle fiber damage and improved repair markers in rodent models, with the proposed mechanism again involving modulation of the local repair microenvironment. The combined use of BPC-157 with other repair peptides such as TB-500 has been proposed as a way to address both the local repair signaling and the broader cellular processes that contribute to repair, although direct head-to-head comparisons of single peptide and combined formulations are still limited in the published literature. For more on the actin-related research peptide that is often paired with BPC-157, see our companion article on TB-500 research and the thymosin beta-4 fragment.

Gastrointestinal Research Models

BPC-157 has its origin in gastric juice research, and the gastrointestinal tract has been one of the most studied organ systems in the BPC-157 literature. Rodent models of gastric ulceration, intestinal injury, and inflammatory conditions have been used to evaluate BPC-157 effects on mucosal repair markers, vascular density at injury sites, and the broader histological recovery of the gastrointestinal mucosa.

Published research on gastric ulcer models has reported that BPC-157 administration is associated with improved mucosal repair endpoints relative to untreated controls. The proposed mechanism in this context involves angiogenesis, modulation of growth factor expression, and effects on the local microvasculature at the site of mucosal damage. These findings are consistent with the broader pattern in BPC-157 research, where the peptide is described as supporting repair processes through local modulation of the injury microenvironment.

The gastrointestinal research literature on BPC-157 also intersects with broader research on the gut-brain axis and on the regulation of intestinal inflammation, which has positioned the peptide within several different preclinical research subfields beyond pure tissue repair.

Angiogenesis Markers in BPC-157 Research

Angiogenesis, the formation of new blood vessels from existing vasculature, is a central process in tissue repair. Without adequate blood supply, repair tissue cannot mature, and the injury site remains vulnerable to further damage or chronic dysfunction. BPC-157 has been studied for its effects on angiogenesis markers in research models, and this is one of the areas where the published mechanistic literature is most developed.

BPC-157 research has reported effects on vascular endothelial growth factor expression, endothelial cell tube formation in vitro, and capillary density at the injury site in rodent models. The proposed mechanism involves modulation of nitric oxide signaling pathways and growth factor expression in the local repair environment. The nitric oxide connection has been studied in particular detail, with research suggesting that BPC-157 interacts with the NO system in ways that influence vascular function during the repair response.

The angiogenic effects of BPC-157 connect to its broader role in tissue repair, since adequate vascularization is required for the maturation of repair tissue across multiple organ systems. The proposed combination of BPC-157 with other research peptides such as TB-500 in formulations like KLOW reflects the conceptual hypothesis that combined effects on local and systemic angiogenesis may produce a more comprehensive repair signal than any single peptide on its own.

BPC-157 in the KLOW Blend

In the KLOW formulation, BPC-157 provides the gastric protective and localized tissue repair component of the blend. It is paired with GHK-Cu for dermal fibroblast research, with TB-500 for systemic tissue repair research, and with KPV for anti-inflammatory research. The pillar article on the KLOW peptide blend discusses how the proposed pathway interactions across these four peptides may produce research signals that are not observable with single peptide studies.

For research handling, BPC-157 is generally well behaved under standard cold storage conditions, but the long term stability of combined peptide formulations is less extensively characterized than the stability of each peptide in isolation. Researchers working with KLOW 90mg should follow good laboratory practice and consult the Certificate of Analysis for peptide identity and purity information.

Open Research Questions

Several open questions remain in BPC-157 research, despite the substantial body of preclinical literature. These include whether the proposed local mechanism of action produces measurable improvements across a broader range of injury types and tissues, whether the combined formulation with TB-500 in research models produces additive or synergistic effects on repair endpoints, and how the proposed nitric oxide and vascular endothelial growth factor mechanisms interact with the broader tissue repair signaling network. Each of these is a legitimate research opportunity, and the existing literature provides a strong foundation for continued preclinical investigation.

Conclusion

BPC-157 research has produced a substantial body of preclinical evidence on tissue repair endpoints in rodent models, with consistent reports of effects on tendon, ligament, muscle, and gastrointestinal repair markers, angiogenesis, and growth factor expression. The peptide is generally described as a localized modulator of the injury microenvironment, and its inclusion in multi-peptide research formulations like KLOW provides a tool for studying combined repair endpoints alongside other complementary peptides. For researchers studying tissue repair pathways, BPC-157 represents one of the most thoroughly characterized peptides in the field.

For more on the full KLOW research cluster, see the pillar overview article and the supporting articles on each constituent peptide.

BPC-157 is supplied by Midwest Peptide for research use only and is not intended for human administration.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

GHK-Cu 50mg, 99%+ purity, COA included
TB-500 10mg, 99%+ purity, COA included
BPC-157 10mg, 99%+ purity, COA included
KLOW 90mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

BPC-157 Research: A Review of Tissue Repair Studies in Animal Models

Frequently Asked Questions

What is BPC-157 in research contexts?

Why is BPC-157 a foundational component of the KLOW blend?

How does BPC-157 in KLOW differ from BPC-157 alone in research?

Is BPC-157 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

What Is BPC-157?

Tendon Repair Studies in Rodent Models

Ligament and Muscle Repair Endpoints

Gastrointestinal Research Models

Angiogenesis Markers in BPC-157 Research

BPC-157 in the KLOW Blend

Open Research Questions

Conclusion

Ready to Start Your Research?

Where can researchers source third-party tested BPC-157?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

BPC-157 Research: A Review of Tissue Repair Studies in Animal Models

Frequently Asked Questions

What is BPC-157 in research contexts?

Why is BPC-157 a foundational component of the KLOW blend?

How does BPC-157 in KLOW differ from BPC-157 alone in research?

Is BPC-157 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

What Is BPC-157?

Tendon Repair Studies in Rodent Models

Ligament and Muscle Repair Endpoints

Gastrointestinal Research Models

Angiogenesis Markers in BPC-157 Research

BPC-157 in the KLOW Blend

Open Research Questions

Conclusion

Related Research Articles

Explore Related Products

Ready to Start Your Research?

Where can researchers source third-party tested BPC-157?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?